Coave Therapeutics Showcases Innovative Capsid Technology at ESGCT
Coave Therapeutics, a leader in genetic medicine innovation, recently presented compelling data regarding its advanced suprachoroidal capsid, coAAV-SCS-01, at the European Society of Gene and Cell Therapy Congress 2025 held in Seville. This innovative capsid has shown to outperform traditional capsids, highlighting its potential to transform treatments for retinal vascular diseases.
Key Findings from the Research
During the congress, Coave's research drew significant attention for comparing the performance of coAAV-SCS-01 against established options like AAV8 and other first and second-generation capsids. According to their findings, coAAV-SCS-01 exhibited up to a remarkable 26-fold increase in effectiveness at targeting retinal pigment epithelium (RPE) and choroid cells compared to its counterparts.
Optimized for Retinal Vascular Diseases
The unique characteristics of coAAV-SCS-01 make it exceptionally suited for addressing retinal vascular conditions such as diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). By utilizing suprachoroidal delivery, this capsid type could facilitate non-invasive, lasting gene therapies that combine efficacy and safety in a user-friendly format.
The Research Backdrop
The presentation at ESGCT included two pivotal studies involving non-human primates (NHPs), wherein coAAV-SCS-01's performance was assessed against a lineup of conventional capsids. The studies confirmed that coAAV-SCS-01 significantly enhanced transduction in targeted areas while minimizing exposure to off-target regions, thus enhancing patient safety.
Notable Study Outcomes
The first study's findings highlighted coAAV-SCS-01's superior ability to target RPE-choroid and retinal cells when tested against various capsids, including AAV2 and AAV7m8. Furthermore, the second study showcased its superior safety profile, marked by reduced targeting of the eye's anterior segment, along with immune evasion capabilities. These aspects are important as they open avenues for potential treatments in cases where both eyes need attention.
Quotes from Leadership
Rodolphe Clerval, the CEO of Coave Therapeutics, expressed excitement regarding these developments, stating, "These data confirm that our suprachoroidal capsid, coAAV-SCS-01, delivers on all key metrics versus existing capsids. The greatly enhanced tissue targeting and transduction, along with the promising safety features, suggest that we are on the verge of a breakthrough in gene therapies for retinal conditions, achievable through a simple procedure as common as an anti-VEGF injection.”
Additional Information from ESGCT 2025
The poster presented by Coave at the conference carried the title "Ligand-conjugated adeno-associated viral (AAV) vectors coAAV-SCS-01.1 and coAAV-SCS-01.2 outperform benchmarks in RPE-choroid and retina transduction after suprachoroidal administration in non-human primates," showcasing the comprehensive research and data analysis conducted by the Coave team.
Upcoming Presentation Details
This insight was shared during an engaging session on Thursday at the congress, led by Lolita Petit, Coave's Chief Scientific Officer, further underscoring the innovation and dedication behind this pioneering research.
About Coave Therapeutics
Coave Therapeutics is at the forefront of developing advanced solutions in genetic medicine aimed at enhancing the precision, safety, and efficacy of treatments targeting various diseases beyond hepatic tissues. Their proprietary ALIGATER™ platform represents a grounded commitment to lead in the competitive landscape of genetic therapies, addressing critical barriers in delivery and effectiveness.
With a robust pipeline focused on conditions such as CNS, neuromuscular, and ocular diseases, Coave is positioned uniquely with the backing of substantial life sciences investors. The company is headquartered in Paris, France, and is on a continuous journey toward transforming the landscape of gene therapy applications for better health outcomes.
Frequently Asked Questions
What was the key focus of Coave's presentation at ESGCT 2025?
Coave focused on its innovative suprachoroidal capsid, coAAV-SCS-01, and its superior performance compared to traditional capsids in targeting retinal cells.
Why is coAAV-SCS-01 considered innovative?
This capsid is recognized for its enhanced tissue specificity and safety, leading to improved targeting of retinal diseases.
What conditions could coAAV-SCS-01 potentially address?
It has the potential to provide treatment solutions for retinal vascular diseases like diabetic macular edema and neovascular age-related macular degeneration.
Who presented Coave's research at the congress?
Lolita Petit, the Chief Scientific Officer, was the presenter of the research findings at ESGCT 2025.
How does Coave Therapeutics aim to enhance gene therapies?
The company utilizes its ALIGATER™ platform to improve the delivery and specificity of gene therapies to target diseases beyond the liver.
